Eikon Therapeutics Revenue and Competitors

Location

#304

Growjo Ranking

3D

Industry

Estimated Revenue & Valuation

  • Eikon Therapeutics's estimated annual revenue is currently $78.8M per year.(i)
  • Eikon Therapeutics's estimated revenue per employee is $215,900
  • Eikon Therapeutics's total funding is $668M.

Employee Data

  • Eikon Therapeutics has 365 Employees.(i)
  • Eikon Therapeutics grew their employee count by 28% last year.

Eikon Therapeutics's People

NameTitleEmail/Phone
1
Chief Scientific OfficerReveal Email/Phone
2
Chief Technology OfficerReveal Email/Phone
3
Associate DirectorReveal Email/Phone
4
Project Manager, Drug DiscoveryReveal Email/Phone
5
Sr Software Product ManagerReveal Email/Phone
6
Senior Scientist 1, Medicinal ChemistryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M110%N/AN/A
#2
$24270M2786321%$4BN/A
#3
$3M2532%N/AN/A
#4
$5.8M43-12%N/AN/A
#5
$0.6M150%$7.5MN/A
#6
$2.9M24-17%N/AN/A
#7
$5M37N/AN/AN/A
#8
$5.2M383%N/AN/A
#9
$9.3M63-9%$122MN/A
#10
$1.8M18-5%N/AN/A
Add Company

What Is Eikon Therapeutics?

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions

keywords:N/A

$668M

Total Funding

365

Number of Employees

$78.8M

Revenue (est)

28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Eikon Therapeutics News

2022-04-06 - Eikon Therapeutics in talks for big lease at unbuilt Millbrae life ...

The publicly traded Pasadena real estate investment trust (NYSE:ARE) is final negotiations with Eikon Therapeutics for 250,000 square feet...

2022-03-30 - Eikon Therapeutics Announces the Election of Kenneth C ...

Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution...

2022-03-22 - Eikon Therapeutics Announces the Appointment of Dr. Roy D ...

Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice...

2021-05-06 - Eikon Therapeutics lands $148M Series A

The Column Group has led a $148 million round for Eikon Therapeutics, the developer of a drug discovery platform that works to treat life-threatening diseases by observing protein movement in living cells. Foresite Capital, Innovation Endeavors and Lux Capital also participated in the funding. C ...

2021-05-05 - Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery

Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. The compan ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$134.4M3918%N/A
#2
$35M3910%N/A
#3
$88.7M3949%N/A
#4
$86.3M4608%N/A
#5
$75M50816%N/A